Skip to main content

Advertisement

Table 1 Characteristics of patients in validation sets I and II

From: A robust blood gene expression-based prognostic model for castration-resistant prostate cancer

  Validation set I (n = 25) Validation set II (n = 66)
Age, years 71 (68, 77) 69 (63, 73)
Gleason ≤6 1 (4.8 %) 5 (10 %)
Gleason = 7 5 (24 %) 16 (32 %)
Gleason ≥8 15 (71 %) 29 (58 %)
Bone metastasis 19 (76 %) 37 (59 %)
Visceral metastasis 3 (12 %) 26 (41 %)
PSA (ng/mL) 38 (7, 437) 221 (39, 657)
Hemoglobin (g/dL) 11.9 (11.2, 13.3) 11.1 (10.0, 12.4)
LDH (U/L) 223 (200, 273) 342 (256, 561)
AP (IU/L) 84 (69, 194) 163 (85, 399)
Prior treatment Docetaxel 7 (28 %) 52 (79 %)
Abiraterone 4 (16 %) 11 (17 %)
Cabazitaxel 5 (20 %) 0
Sipuleucel-T 3 (12 %) 0
Enzalutamide 2 (8 %) 0
Number of different prior treatments 0 13 (52 %) 14 (21 %)
1 4 (16 %) 41 (62 %)
2 8 (32 %) 11 (17 %)
Median follow-up, months 28.9 30.8
Number of events 15 58
  1. Data are median (0.25 quantile, 0.75 quantile) or count (%). Median follow-up time was calculated based on survivors. All samples in validation set II were drawn right before the next treatment. The samples in validation set I were obtained either right before the next treatment or between two treatments. None of these blood samples were collected immediately after a treatment to reduce the acute impact of treatments